RhoGAM / Rh Immunoglobulin

An Rh-negative mother carrying an Rh-positive baby won't have a problem with her first pregnancy — but without RhoGAM, the second pregnancy could be fatal for the fetus.

RhoGAM (Rh₀(D) immune globulin) is a passive immunization given to Rh-negative mothers to prevent isoimmunization — the formation of maternal anti-D antibodies that would attack Rh-positive fetal red blood cells in future pregnancies. The mechanism is straightforward: injected anti-D antibodies coat any fetal Rh-positive cells that have entered maternal circulation and destroy them before the mother's immune system can recognize them and mount its own active antibody response. Standard timing is 28 weeks gestation (antepartum dose) and within 72 hours after delivery if the newborn is confirmed Rh-positive. RhoGAM is also required after any event that risks fetomaternal hemorrhage: miscarriage, ectopic pregnancy, amniocentesis, chorionic villus sampling, abdominal trauma, or manual placenta removal. The indirect Coombs test (antibody screen) must be negative before administration — a positive result means sensitization has already occurred, and RhoGAM will not reverse it. The standard IM dose is 300 mcg for events after 12 weeks gestation; a smaller 50 mcg (MICRhoGAM) dose is used for first-trimester events. RhoGAM is a blood product, requiring informed consent and proper documentation including lot number.

Key Distinctions

Don't confuse the indirect Coombs (screens maternal blood for anti-D antibodies — done before giving RhoGAM) with the direct Coombs (tests the newborn's RBCs for attached antibodies — done after birth). Students often think RhoGAM treats an already-sensitized mother; it only prevents sensitization. RhoGAM is given to the mother, never the baby — yet the purpose is protecting future fetuses, not the current pregnancy.

Clinical Pearl

RhoGAM is prevention, not treatment. Once Mom is sensitized (positive indirect Coombs), RhoGAM can't undo it — the window is closed forever.